WHO ICTRP trial
To Evaluate the Efficacy and Safety of CD19, BCMA CAR-T Cell Immunotherapy for…
ChiCTR2000028920 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR2000028920 |
|---|---|
| Public title | To Evaluate the Efficacy and Safety of CD19, BCMA CAR-T Cell Immunotherapy for Relapse /Refractory Multiple Myeloma Patients: a Single Center, Single Arm, Open Clinical Trial. |
| Scientific title | To Evaluatie the Efficacy and Safety of CD19, BCMA CAR-T Cells Immunotherapy for Relapse /Refractory Multiple Myeloma Patients: a Single Center, Single Arm, Open Clinical Trial. |
| Primary sponsor | The Third Affiliated Hospital of Kunming Medical University |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional study |
| Phase | 0 |
| Countries | China |
| Conditions | Multiple Myeloma |
| Interventions | single arm:CD19, BCMA CAR-T Cells Immunotherapy |
| Registration date | Jan 7, 2020 |
| Target size | single arm:30 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: